Galectin TherapeuticsCorporate OverviewJanuary 2025 2 This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 19

Galectin TherapeuticsCorporate OverviewJanuary 2025

2 This presentation contains, in addition to historical information,

forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance and use words such as "may," "estimate," "could," "expect" and

others. They are based on our current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements.These statements include those regarding potential

therapeutic benefits of our drugs, expectations, plans and timelines related to our clinical trials, supporting activities, potential partnering opportunities and estimated spending for 2024 and beyond. Factors that could cause our actual

performance to differ materially from those discussed in the forward-looking statements include, among others, that our trials and supporting CMC information may be impacted by a resurgence of COVID-19 or a similar outbreak of an infectious

disease.We may experience delays in our trials, which could include enrollment delays. Future phases or future clinical studies may not begin or produce positive results in a timely fashion, if at all, and could prove time consuming and

costly. Plans regarding development, approval and marketing of any of our drugs are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. Strategies and spending

projections may change. We may be unsuccessful in developing partnerships with other companies or obtaining capital that would allow us to complete our clinical trials or further develop and/or fund any future studies or trials.To date, we

have incurred operating losses since our inception, and our future success may be impacted by our ability to manage costs and finance our continuing operations. For a discussion of additional factors impacting our business, see our Annual

Report on Form 10-K for the year ended December 31, 2023, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any

obligation to update forward-looking statements. Forward-Looking Statements

Belapectin is a novel, potent, galectin-3 inhibitor with Fast Track

Designation Low toxicity as a carbohydrate-based molecule which is degraded by natural processes Patent protection through 2033 Only company to exclusively focus on treatment for MASH cirrhosis and portal hypertension Significant

efficacy observed in cirrhotic patients without varices Promising NAVIGATE topline results at 18 month read out, 40% reduction in new varices vs placebo in ITT; significantly lower incidence of new varices in per protocol

population Encouraging clinical response in difficult-to-treat cancers in combination with checkpoint inhibitor IND filed and approval to proceed received from FDA (Head & Neck cancer) Developing galectin-based therapeutics to improve

the lives of patients with chronic liver diseases and cancer Focused Pipeline MASH Cirrhosis Oncology (Combination Therapy) Investment Highlights 3

Highly Experienced Leadership Team 4 Over 32 years of public and private

company experience including more than a decade of audit, tax and SEC registrant experience with a major accounting firm. JACK W. CALLICUTT Chief Financial Officer Over 28 years of experience working in the pharmaceutical industry in

clinical data and trial management with 23 years as statistician. SETH ZUCKERMANSenior Director, Biostatistics Over 25 years diverse experience in the pharmaceutical research industry supporting global study operations from site to

personnel management. JESSICA KOPACZEWSKI Senior Director, Clinical Operations Highly experienced in pharmaceutical development of novel formulations and medicines with advanced manufacturing techniques and bringing them to

approval. JEFF KATSTRA VP, CMC / Pharmaceutical Development Extensive experience in clinical pharmacology, drug metabolism, and pharmacokinetics with various drug formats and across therapeutic areas, leading to 10 different global drug

approvals. EZRA LOWE, Ph.D. VP, Clinical and Preclinical Pharmacology Financial executive with over 25 years of management experience in a taxation, restructuring, acquisition, and private equity ventures. JOEL LEWIS Chief Executive

Officer & President Have two decades of expereince leading drug development across various stages of clinical trials in the pharmaceutical industry. Led multiple new drug application filings and secured approvals from several regulatory

agencies. KHURRAM JAMIL, M.D.Chief Medical Officer More than 20 years of domestic and international drug development experience encompassing all aspects of global Regulatory Affairs and Quality Assurance. SUE THORNTON VP Regulatory

Clinical Program Development

Stage Drug Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Fibrosis Belapectin MASH Cirrhosis and Portal Hypertension Cancer Immunotherapy (Combination therapy) Belapectin + Keytruda Melanoma + Head / Neck Cancer Oral

Galectin-3 Inhibitors Discovery program to identify subcutaneous forms of carbohydrates and oral small molecules 5 Laser-Focused Pipeline

Galectin 3 is part of the galectin family of sugar-binding proteins that act as

a "molecular glue", it is: Predominantly produced by activated macrophages Involved in a wide number of biological and pathological processes Galectin-3 recruits macrophages to injury sites and promotes chronic inflammation by activating

proinflammatory pathways 1. Marino KV, et al. Nat Rev Drug Discov. 2023;22(4):295-316. 2. Henderson NC, et al. Proc Natl Acad Sci U S A. 2006;103(13):5060-5. Galectin-3 drives many pathophysiological process in fibrotic diseases and

cancer 6 Galectin-3 is a Promising Therapeutic Target in Inflammatory and Fibrotic Diseases1,2 Proliferation Inflammation Fibrosis Apoptosis Adhesion Angiogenesis Metastasis Tumor Growth Differentiation Migration Galectin-3

Belapectin: a Proprietary Galectin-3 Inhibitor with Low Toxicity and

Anti-fibrotic Activity Belapectin is a polysaccharide polymer comprising galacturonic acid, galactose, arabinose, rhamnose and smaller amounts of other sugars Belapectin Preclinical Data: In animal models of MASH (streptozotocin High-Fat

Diet mice1) and cirrhosis (thioacetamide treated rats2) belapectin was associated with decreased: Galectin-3 staining and galectin-3 expression in macrophages NAFLD Activity Scores Collagen-1 expression Hepatic collagen

deposition Hepatic fibrosis Portal pressure In toxicology studies, including monkeys, belapectin: Was well-tolerated even at high doses Accumulated in macrophages with a residence time longer than in plasma 1. Traber PG, et al. PLoS

One. 2013;8(12):e83481. 2. Traber PG, et al. PLoS One. 2013; ;8(10):e75361. 7

MASH Cirrhosis Represents a Significant Market Opportunity in the U.S. with No

FDA-Approved Treatment Metabolic dysfunction-associated steatohepatitis (MASH), previously known as non-alcoholic steatohepatitis (NASH), is characterized by fat accumulation, inflammation and fibrosis of the liver1 3%-5% of the global

population is estimated to be affected by MASH, though the disease is considered to be underdiagnosed2 There are genetic predisposition to MASH, yet certain health conditions put patients at increased risk:3 1. Fatty Liver Foundation.

https://www.fattyliverfoundation.org/#gsc.tab=0. .2. Sherif ZA, et al. Dig Dis Sci. 2016;61(5):1214-25. 3. NIDDK. NAFLD and MASH. https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash/symptoms-causes. 4. Datamonitor

Healthcare. MASH Disease Analysis. 5. Scientific Registry of Transplant Recipients. OPTN/SRTR 2021 Annual Data Report: Liver. https://srtr.transplant.hrsa.gov/annual_reports/2021/Liver.aspx. 6. Stepanova M, et al. Hepatol Commun.

2022;6(7):1506-1515. 5M Progress to MASH cirrhosis1 20M Develop liver fibrosis1 100M Americans have fatty liver disease (most don't know it)1 Only curative treatment is liver transplant1 30% of those listed for liver transplant

will die waiting1 MASH cirrhosis is expected to become the most frequent reason for a liver transplant6 Prevalence increased >2x in the past decade 4 Addressable market in the U.S. ~8.7K Liver transplantations in the U.S.5 Being

overweight or obese Having hypertension, high cholesterol or high triglyceride levels Having type 2 diabetes, insulin resistance or prediabetes 9

10 3rd Party Market Opportunity Assessment Suggests1 Potential 50-100%

Adoption Rate Limited current treatment options: Cirrhotic management focuses on stabilization and delaying progression Management directed towards comorbidities Highly favorable perception of belapectin indication, MoA and safety by HCPs

Payers believe in the high unmet need in MASH cirrhosis Belapectin is a Novel Therapy with First- and Best-in-Class Potential in MASH Cirrhosis 1. LifeSci Consulting Belapectin Commercial Opportunity Assessment contracted by the

Company. May 2024. United States Estimates1 A significant unmet need exists for MASH compensated cirrhosis patients with portal hypertension due to disease severity and risk of decompensation $8.8B 2.1M 331K Patients with compensated

MASH cirrhosis in 2024 Peak belapectin sales in U.S. Patients with compensated cirrhosis and portal hypertension with no varices in 2024

HPVG=hepatic venous pressure gradient. There are no approved therapies to

reverse portal hypertension once it develops in MASH Cirrhosis When to Intervene in Cirrhosis- before its too late! 11 Compensated cirrhosis Decompensated cirrhosis No Portal Hypertension Portal Hypertension Stage 2 Stage 3 and

4 No varices No varices Varices, small to large Varices Bleeding, ascites, encephalopathy HVPG1 mm Hg One year mortality 1-3% One year mortality ~50% 6 >10

Phase 2b Study of Belapectin in Patients with MASH Cirrhosis: GT-026 Trial

12 Placebo n=54 Screen Belapectin 8 mg/kg/LBM Q2W n=54 52 Weeks Belapectin 2 mg/kg/LBM Q2W n=53 Randomize (N=162 1:1:1) Main inclusion criteria MASH cirrhosis (biopsy) Portal Hypertension: HVPG 6 mmHg No cirrhosis

complications No varices/varices (50:50) Primary endpoint Portal pressure (HPVG) change from baseline to Week 54 Secondary endpoints at Week 54 Liver biopsy Varices (esophago-gastric endoscopy) Cirrhosis decompensation HVPG = Hepatic

Venous Pressure Gradient; LBM=lean body mass. 1. Chalasani N, et al. Gastroentrol. 2020;158:1334-45.

Belapectin Impact on HPVG at One Year1,* 13 HVPG = Hepatic Venous Pressure

Gradient; LBM=lean body mass, N.S.=non significant. *ITT with LOCF, ANCOVA with baseline as covariate and treatment as factors, Bonferroni-Holm.1. Chalasani N, et al. Gastroentrol. 2020;158:1334-45. N.S. N.S. Baseline 1 yr Baseline 1

yr Baseline 1 yr Baseline p=0.02 p=0.44 ITT Population Subjects with no varices at baseline

Belapectin Reduces Emergence of Varices in Patients with MASH Cirrhosis1,*

14 Significantly fewer new varices on belapectin vs placebo No patients on 2 mg/kg/LBM developed new varices Belapectin demonstrated efficacy on a clinically-meaningful endpoint where no current therapies exist LBM=lean body mass. *Chi

square 1. Chalasani N, et al. Gastroentrol. 2020;158:1334-45. p=0.02 p=0.12

NAVIGATE Trial: Belapectin for Prevention of Varices in Patients with MASH

cirrhosis and Portal Hypertension 15 Placebo n=119 Screen Belapectin 2 mg/kg/LBM Q2W n=119 78 Weeks Belapectin 4 mg/kg/LBM Q2W n=119 Randomize (N=357 1:1:1) Patient Population MASH cirrhosis Diagnosis of Portal Hypertension

using Baveno criteria (via non-invasive markers as per latest guidelines) EGDs assessed via central review by multiple blinded reviewers. Originally the NAVIGATE trial was designed as an adaptive Phase 2b/3 trial for 36-month duration.

However, based on FDA feedback, the Company made the decision to analyze the stage 1 (18 month) as stand-alone clinical trial. LBM- Lean body mass; EGD=Esophagogastroduodenoscopy

NAVIGATE Study: Patient Population and Efficacy Endpoints 16 MASH

cirrhosis No varices on EGD CTP Scores <7 Portal hypertension: Thrombocytopenia or at least AST/ALT > 1 Spleen 14 cm Collaterals by imaging Stiffness 20 kPa Development of new varices (composite strategy) in ITT

population- Number of subjects with varices Subject with intercurrent events (ICE*) Subject with missing EGDs and no ICE Pre-defined per protocol population- Development of new varices per protocol Hepatic decompensation

events All-cause mortality Proportion of patients with large varices or red wales Varices requiring treatment MELD 15 Liver transplant Non-invasive biomarkers ALT=alanine aminotransferase ; AST=aspartate transaminase;

CTP=Child-Turcotte-Pugh; MELD=model for end-stage liver disease. *Intercurrent events include; Liver related clinical events, any AE leading to discontinuation, TIPS; 12-month use of GLP-1 or NSBB Key inclusion criteria Primary

endpoint Secondary endpoint

Baseline demographics Table 14.1.3.1 17 2014 Galectin Therapeutics | NASDAQ:

GALT Baseline Demographics and Clinical Characteristics (n=355) Placebo (N = 118) 2mg/kg LBM (N = 119) 4mg/kg LBM (N = 118) Mean (Standard Deviation) Mean (Standard Deviation) Mean (Standard Deviation) Age (years) 60.4

(8.50) 60.6 (8.82) 59.0 (9.14) Gender (female), n 72 (61.0) 75 (63.0) 83 (70.3) Ethnicity (Hispanic), n 34 (28.8) 39 (32.8) 33 (28.0) Race (white), n 104 (88.1) 107 (89.9) 111 (94.1) Weight (kg) 94.2 (21.68) 98.1

(24.30) 94.6 (20.95) BMI (Kg/m2) 33.82 (6.467) 34.88 (6.683) 34.53 (6.223) Hypertension 89 (75.4) 89 (74.8) 82 (69.5) Type 2 Diabetes 80 (67.8) 79 (66.4) 79 (66.9) HbA1C % 6.4 (1.27) 6.3 (1.13) 6.4 (1.09) Alanine

Aminotransferase (ALT), U/L 46.3 (29.92) 38.9 (26.88) 39.7 (20.22) Aspartate Aminotransferase (AST), U/L 46.7 (23.52) 41.8 (24.40) 43.6 (21.90) Platelets (per L) 130.1 (39.66) 127.6 (48.39) 136.4 (53.62) Liver Stiffness

Measurement (kPa) 24.22 (12.179) 24.63 (13.548) 25.67 (13.196) Spleen (cm) 13.79 (2.750) 13.97 (2.602) 13.87 (2.436) MELD Score 7.6 (1.65) 7.9 (2.46) 7.5 (1.55) Child Pugh Score 5.1 (0.29) 5.1 (0.31) 5.0 (0.18) Statins

(n) 49 (41.5) 55 (46.2) 47 (39.8) GLP-1 agonist (n) 24 (20.3) 26 (21.8) 27 (22.9)

NAVIGATE 18-month Primary Analyses Result 18 2014 Galectin Therapeutics |

NASDAQ: GALT ITT: All randomized subjects Primary end point composite strategy i.e. new varices and or intercurrent events or drop out ICEs (intercurrent events) include; Liver related clinical events, AE leading to discontinuation, TIPS;

12-month use of GLP-1 or NSBB Overall Target Significance level - 2-sided p value of 0.05; p: 0.048, using CMH test, stratified by Type 2 diabetes status at randomization. The categories are not mutually exclusive. p 0.139 p 0.552 n =

NAVIGATE 18-month Primary Analyses Result 19 2014 Galectin Therapeutics |

NASDAQ: GALT Per protocol population Per Protocol: All ITT subjects who completed 18 months of treatment and an end of treatment (EOT) EDG Overall Target Significance level - 2-sided p value of 0.05; using CMH test, stratified by Type 2

diabetes status at randomization. p-value: <0.05 p-value: 0.119 n = 95 n =97 n = 98

20 2014 Galectin Therapeutics | NASDAQ: GALT Categorical Changes in Liver

Stiffness Measure LSM (kPa) Baseline to 18 month Per-Protocol (N = 277)Table 14.2.5.1.1.3 Belapectin Placebo (N = 92) 2mg/kg LBM (N = 93) 4mg/kg LBM (N = 92) Baseline LSM Value (kPA) Mean (SD) 23.3 (11.1) 22.9 (10.6) 24.4

(11.8 ) Median 22.4 21.5 23.4 W78/EOT LSM Value (kPa) Mean (SD) 22.5 (13.6) 21.2 (12.9) 22.8 (13.8) Change from Baseline in W78/EOT LSM Value (kPa) Mean (SD) -0.8 (11.8) -1.7 (9.7) -1.5 (12.6) % Change from Baseline in W78/EOT

LSM Value (kPa) * Mean % 9.9 -4.3 9.3 * Percentage change calculated for each individual subject

Categorical Changes in ELF Score- Baseline to 18 months Per-Protocol Table

14.2.5.1.2.2 (N: 275) 21 2014 Galectin Therapeutics | NASDAQ: GALT ELF Enhanced Liver Fibrosis Score- combined for HA, PIIINP and TIMP-1 ELF: Risk of disease progression. < 9.8 Low risk, 11.3 mid risk, highest risk 13

Belapectin Placebo 2mg/kg LBM 4mg/kg LBM Baseline ELF Value N 87 93 95 Mean 10.68 10.55 10.58 SD 1.1621 0.9608 1.0433

Lack of Dose Response at Higher Doses of Belapectin in GT-026 were also observed

in NAVIGATE trial Based on findings from preclinical and clinical trials to date, Belapectin likely demonstrates target-mediated drug disposition (TMDD) Once Galectin-3 binding sites within macrophages are saturated, additional drug

molecules do not enhance efficacy Higher doses may exceed the macrophage-specific uptake mechanisms, resulting in inefficient drug distribution or clearance Higher drug concentrations have been associated with reduced efficacy, as observed

in the GT-026 cohort, where subjects receiving 8 mg/kg (with higher AUC) exhibited lower pharmacodynamic (PD) effects. Similar PK profile shown by monoclonal antibodies and interferon among other agents. 2 mg/kg dose demonstrated consistent

and most optimum efficacy response Similar PK-PD effects were observed across the GT-026 trial and the NAVIGATE 18-month results 22 2014 Galectin Therapeutics | NASDAQ: GALT Chalasani et al. Gastroenterology 2020; 158:

1334-1345 Pharmacokinetic-Pharmacodynamic (PK-PD)

Summary of safety results Similar proportion of subjects discontinued the study